Company News for Jul 26, 2024
AbbVie Inc.’s (ABBV) shares advanced 3.4% after the company reported second-quarter 2024 adjusted earnings per share of $2.65, surpassing the Zacks Consensus Estimate of $2.57. Shares of Valero Ener...
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| 3335.6101 | |
| 3335.6101 | |
| - | |
| 3335.6101 | |
| 3335.6101 | |
| 2309.1619-3362 | |
| 5 936 855 M | |
| 55.0696 | |
| 1 766 M | |
| 54 403 M | |
| 0.0341 | |
| 0.623 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
AbbVie Inc.’s (ABBV) shares advanced 3.4% after the company reported second-quarter 2024 adjusted earnings per share of $2.65, surpassing the Zacks Consensus Estimate of $2.57. Shares of Valero Ener...
Participants Liz Shea; Investor Relations; AbbVie Inc Robert Michael; President, Chief Executive Officer, Director; AbbVie Inc Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; A...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: